Alkermes plc $ALKS Stock Position Increased by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund increased its position in Alkermes plc (NASDAQ:ALKS – Free Report) by 36.2% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 114,142 shares of the company’s stock after purchasing an additional 30,368 shares during the period. Illinois Municipal Retirement Fund’s holdings in Alkermes were worth $4,625,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. M&G PLC purchased a new position in Alkermes during the 3rd quarter worth approximately $14,368,000. Allspring Global Investments Holdings LLC increased its position in Alkermes by 236.1% during the third quarter. Allspring Global Investments Holdings LLC now owns 85,682 shares of the company’s stock worth $3,474,000 after buying an additional 60,188 shares during the period. Pictet Asset Management Holding SA increased its position in Alkermes by 20.4% during the third quarter. Pictet Asset Management Holding SA now owns 1,009,318 shares of the company’s stock worth $41,012,000 after buying an additional 171,292 shares during the period. CenterBook Partners LP increased its position in Alkermes by 88.3% during the third quarter. CenterBook Partners LP now owns 13,938 shares of the company’s stock worth $565,000 after buying an additional 6,535 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Alkermes in the third quarter valued at approximately $347,000. 95.21% of the stock is owned by hedge funds and other institutional investors.

Alkermes Price Performance

Shares of ALKS opened at $47.03 on Monday. Alkermes plc has a fifty-two week low of $27.00 and a fifty-two week high of $55.67. The company has a market capitalization of $7.90 billion, a price-to-earnings ratio of -2,350.32 and a beta of 0.32. The firm has a 50-day simple moving average of $43.67 and a 200-day simple moving average of $41.13. The company has a debt-to-equity ratio of 0.79, a quick ratio of 2.02 and a current ratio of 2.42.

Alkermes (NASDAQ:ALKS – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported $0.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.17. The firm had revenue of $480.13 million for the quarter, compared to analyst estimates of $463.48 million. Alkermes had a positive return on equity of 0.40% and a negative net margin of 0.02%. The business’s revenue was up 21.8% on a year-over-year basis. During the same quarter last year, the company posted $0.49 earnings per share. On average, equities research analysts anticipate that Alkermes plc will post -0.52 earnings per share for the current year.

Insider Activity at Alkermes

In other Alkermes news, EVP Craig C. Hopkinson sold 9,000 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $46.99, for a total transaction of $422,910.00. Following the completion of the sale, the executive vice president directly owned 65,389 shares of the company’s stock, valued at approximately $3,072,629.11. This trade represents a 12.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP David Gaffin sold 2,035 shares of Alkermes stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $46.17, for a total value of $93,955.95. Following the completion of the transaction, the executive vice president owned 219,353 shares in the company, valued at $10,127,528.01. This trade represents a 0.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 15,103 shares of company stock valued at $697,973. 4.59% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ALKS. Piper Sandler reiterated an “overweight” rating and issued a $65.00 price objective (up from $43.00) on shares of Alkermes in a research note on Tuesday, July 28th. Robert W. Baird set a $61.00 target price on shares of Alkermes in a research report on Wednesday, November 4th. The Goldman Sachs Group began coverage on shares of Alkermes in a report on Thursday, September 24th. They issued a “neutral” rating and a $50.00 target price on the stock. Royal Bank Of Canada lifted their target price on shares of Alkermes from $56.00 to $57.00 and gave the company an “outperform” rating in a report on Wednesday, November 4th. Finally, TD Cowen reiterated a “buy” rating on shares of Alkermes in a research report on Monday, September 21st. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $55.73.

View Our Latest Stock Analysis on ALKS

About Alkermes

(Free Report)

Alkermes plc is a biopharmaceutical company focused on developing and commercializing medicines for neuroscience-related conditions, including serious mental illness and addiction. Founded in 1987, the company has operations in the United States and Ireland, with its corporate headquarters in Dublin and major U.S. operations in Massachusetts. Its marketed medicines include Vivitrol, an extended-release injectable formulation of naltrexone used to treat alcohol dependence and to prevent relapse to opioid dependence after detoxification; Aristada, an injectable treatment for schizophrenia in adults; and Lybalvi, a medicine for schizophrenia and bipolar I disorder in adults.

Featured Articles

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes plc (NASDAQ:ALKS – Free Report).

Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.